| Date | Title | Description | |
|---|---|---|---|
| 23 Feb 2022 | Annual Report regarding remuneration of the members of the Board of Directors | ROVI releases the 2021 annual report regarding remuneration of the members of the Board of Directors | Download |
| 23 Feb 2022 | Annual Corporate Governance Report | ROVI releases the 2021 Annual Corporate Governance Report | Download |
| 21 Feb 2022 | Share buy-back , stabilisation and treasury stock programme | Share Buyback Program: transactions conducted between 14 February 2022 and 21 February 2022 | Download |
| 15 Feb 2022 | On business and financial situation | ROVI has announced that the European Commission has authorised the marketing of Okedi® for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone. | Download |
| 14 Feb 2022 | Share buy-back , stabilisation and treasury stock programme | Share Buyback Program: transactions conducted between 7 February 2022 and 11 February 2022 | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 26 Jul 2018 | Información sobre resultados | ROVI releases the press release related to the 2018 first half financial results | Download |
| 02 Jul 2018 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted in the second quarter of 2018 | Download |
| 22 Jun 2018 | Información sobre dividendos | The Company informs about the dividends payment | Download |
| 12 Jun 2018 | Otros sobre negocio y situación financiera | Corporate presentation update | Download |
| 29 May 2018 | Convocatorias y acuerdos de Juntas y Asambleas generales | ROVI releases the information related to its General Shareholders Meeting | Download |